NASDAQ:CALT Calliditas Therapeutics AB (publ) (CALT) Stock Price, News & Analysis $40.00 0.00 (0.00%) As of 09/12/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsOptions ChainOwnershipSEC FilingsTrendsBuy This Stock About Calliditas Therapeutics AB (publ) Stock (NASDAQ:CALT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CALT alerts:Sign Up Key Stats Today's Range$40.00▼$40.0050-Day Range$40.00▼$40.0052-Week Range$15.25▼$43.00VolumeN/AAverage Volume10,339 shsMarket Capitalization$1.19 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Calliditas Therapeutics AB (publ) is a Sweden-based biopharmaceutical company dedicated to the development and commercialization of novel therapies for rare immunologic and renal diseases. The company’s scientific focus centers on targeting the underlying causes of immune-mediated conditions with oral and biologic formulations. By leveraging proprietary drug delivery technologies, Calliditas aims to bring differentiated treatments to patients who currently have limited therapeutic options. The company’s lead product, Tarpeyo® (budesonide) delayed-release capsules, received U.S. Food and Drug Administration (FDA) approval in October 2021 for the treatment of adults with primary immunoglobulin A (IgA) nephropathy at risk of rapid disease progression. Calliditas holds exclusive commercial rights for Tarpeyo in North America and several other territories, and it continues to pursue regulatory submissions and market access efforts in Europe and select international markets. In parallel, the company is advancing a preclinical pipeline of novel immunomodulatory compounds aimed at expanding its rare disease portfolio. Founded in 2004 and headquartered in Stockholm, Calliditas Therapeutics maintains operations across Europe and North America, supported by a corporate office in Boston to oversee U.S. commercialization activities. The company is publicly traded on the Nasdaq Stockholm exchange as well as on the Nasdaq Global Select Market in the United States under the ticker symbol CALT. Calliditas is led by an experienced management team with backgrounds in biopharmaceutical research, regulatory affairs and commercial strategy, positioning the company to execute its growth plans in the global rare disease arena.AI Generated. May Contain Errors. Read More Receive CALT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Calliditas Therapeutics AB (publ) and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CALT Stock News HeadlinesCalliditas Therapeutics AB (publ) (NASDAQ:CALT) vs. Capstone (OTCMKTS:CAPS) Critical ReviewSeptember 12 at 2:17 AM | americanbankingnews.comCalliditas Therapeutics’ Setanaxib Study: A Potential Game-Changer for Alport SyndromeAugust 14, 2025 | msn.comA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boom. For retirees, that could mean a way to generate reliable monthly income—without the outdated 4% withdrawal rule, risky trading, or high-fee annuities. If you’re ready to stop worrying about money running out and start enjoying the freedom to cover expenses, treat loved ones, and live life on your terms, this may be exactly what you’ve been waiting for.September 15 at 2:00 AM | Investors Alley (Ad)Calliditas Therapeutics to Present Four Abstracts at American Society of Nephrology (ASN) Kidney Week 2024October 17, 2024 | tmcnet.comCalliditas Therapeutics (NASDAQ:CALT) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.comDelisting of Calliditas Therapeutics AB (publ) from Nasdaq StockholmSeptember 16, 2024 | prnewswire.comNotice of extraordinary meeting of Calliditas Therapeutics AB (publ)September 3, 2024 | prnewswire.comCalliditas Therapeutics takes certain corporate actions following announcement by Asahi KaseiSeptember 3, 2024 | prnewswire.comSee More Headlines CALT Stock Analysis - Frequently Asked Questions How have CALT shares performed this year? Calliditas Therapeutics AB (publ)'s stock was trading at $40.0001 at the beginning of 2025. Since then, CALT shares have increased by 0.0% and is now trading at $40.0001. How were Calliditas Therapeutics AB (publ)'s earnings last quarter? Calliditas Therapeutics AB (publ) (NASDAQ:CALT) announced its quarterly earnings results on Tuesday, August, 13th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.09. The firm had revenue of $52.36 million for the quarter, compared to the consensus estimate of $42.89 million. Calliditas Therapeutics AB (publ) had a negative net margin of 30.18% and a negative trailing twelve-month return on equity of 212.04%. Read the conference call transcript. When did Calliditas Therapeutics AB (publ) IPO? Calliditas Therapeutics AB (publ) (CALT) raised $179 million in an IPO on Friday, June 5th 2020. The company issued 9,200,000 shares at a price of $19.50 per share. Citigroup, Jefferies and Stifel acted as the underwriters for the IPO and Carnegie was co-manager. How do I buy shares of Calliditas Therapeutics AB (publ)? Shares of CALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Calliditas Therapeutics AB (publ) own? Based on aggregate information from My MarketBeat watchlists, some other companies that Calliditas Therapeutics AB (publ) investors own include Advanced Micro Devices (AMD), Celsius (CELH), NIO (NIO), NVIDIA (NVDA), Reata Pharmaceuticals (RETA), Target (TGT) and Athenex (ATNX). Company Calendar Last Earnings8/13/2024Today9/15/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CALT CIK1795579 Webwww.calliditas.se Phone46-0-841-130-05FaxN/AEmployees180Year Founded2004Profitability EPS (Trailing Twelve Months)($1.85) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$43.96 million Net Margins-30.18% Pretax Margin-29.40% Return on Equity-212.04% Return on Assets-27.96% Debt Debt-to-Equity Ratio9.44 Current Ratio2.69 Quick Ratio2.59 Sales & Book Value Annual Sales$1.60 billion Price / Sales0.74 Cash FlowN/A Price / Cash FlowN/A Book Value$1.06 per share Price / Book37.74Miscellaneous Outstanding Shares29,790,000Free Float29,135,000Market Cap$1.19 billion OptionableOptionable Beta1.77 Social Links These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:CALT) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calliditas Therapeutics AB (publ) Please log in to your account or sign up in order to add this asset to your watchlist. Share Calliditas Therapeutics AB (publ) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
